{"resourceType":"CodeSystem","id":"ssf-2-leukemia-codesystem","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This case-sensitive code system <code>https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">000<a name=\"ssf-2-leukemia-codesystem-000\"> </a></td><td>正常</td></tr><tr><td style=\"white-space:nowrap\">001<a name=\"ssf-2-leukemia-codesystem-001\"> </a></td><td>AML with RUNX1-RUNX1T1</td></tr><tr><td style=\"white-space:nowrap\">002<a name=\"ssf-2-leukemia-codesystem-002\"> </a></td><td>AML with CBFB-MYH11</td></tr><tr><td style=\"white-space:nowrap\">003<a name=\"ssf-2-leukemia-codesystem-003\"> </a></td><td>Acute promyelocytic leukemia with PML-RARA</td></tr><tr><td style=\"white-space:nowrap\">004<a name=\"ssf-2-leukemia-codesystem-004\"> </a></td><td>AML with KMT2A-MLLT3</td></tr><tr><td style=\"white-space:nowrap\">005<a name=\"ssf-2-leukemia-codesystem-005\"> </a></td><td>AML with DEK-NUP214</td></tr><tr><td style=\"white-space:nowrap\">006<a name=\"ssf-2-leukemia-codesystem-006\"> </a></td><td>AML with GATA2, MECOM</td></tr><tr><td style=\"white-space:nowrap\">007<a name=\"ssf-2-leukemia-codesystem-007\"> </a></td><td>AML(megakaryoblastic) with RBM15-MKL1</td></tr><tr><td style=\"white-space:nowrap\">008<a name=\"ssf-2-leukemia-codesystem-008\"> </a></td><td>AML with mutated NPM1</td></tr><tr><td style=\"white-space:nowrap\">009<a name=\"ssf-2-leukemia-codesystem-009\"> </a></td><td>AML with biallelic mutation of CEBPA</td></tr><tr><td style=\"white-space:nowrap\">010<a name=\"ssf-2-leukemia-codesystem-010\"> </a></td><td>AML with mutated FLT3/ITD</td></tr><tr><td style=\"white-space:nowrap\">011<a name=\"ssf-2-leukemia-codesystem-011\"> </a></td><td>AML with mutated FLT3/TKD</td></tr><tr><td style=\"white-space:nowrap\">012<a name=\"ssf-2-leukemia-codesystem-012\"> </a></td><td>AML with MLL-PTD (partial tandem duplication)</td></tr><tr><td style=\"white-space:nowrap\">013<a name=\"ssf-2-leukemia-codesystem-013\"> </a></td><td>AML with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">021<a name=\"ssf-2-leukemia-codesystem-021\"> </a></td><td>B lymphoblastic leukemia/lymphoma with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">022<a name=\"ssf-2-leukemia-codesystem-022\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged</td></tr><tr><td style=\"white-space:nowrap\">023<a name=\"ssf-2-leukemia-codesystem-023\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)</td></tr><tr><td style=\"white-space:nowrap\">024<a name=\"ssf-2-leukemia-codesystem-024\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with IGH/IL3</td></tr><tr><td style=\"white-space:nowrap\">025<a name=\"ssf-2-leukemia-codesystem-025\"> </a></td><td>B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)</td></tr><tr><td style=\"white-space:nowrap\">041<a name=\"ssf-2-leukemia-codesystem-041\"> </a></td><td>Mixed phenotype acute leukemia with BCR-ABL1</td></tr><tr><td style=\"white-space:nowrap\">042<a name=\"ssf-2-leukemia-codesystem-042\"> </a></td><td>Mixed-phenotype acute leukemia with KMT2A-rearranged</td></tr><tr><td style=\"white-space:nowrap\">051<a name=\"ssf-2-leukemia-codesystem-051\"> </a></td><td>Chronic myelogenous leukemia BCR-ABL1 positive</td></tr><tr><td style=\"white-space:nowrap\">052<a name=\"ssf-2-leukemia-codesystem-052\"> </a></td><td>JAK2 V617F mutation</td></tr><tr><td style=\"white-space:nowrap\">053<a name=\"ssf-2-leukemia-codesystem-053\"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRA rearrangement</td></tr><tr><td style=\"white-space:nowrap\">054<a name=\"ssf-2-leukemia-codesystem-054\"> </a></td><td>Myeloid and lymphoid neoplasms with PDGFRB rearrangement</td></tr><tr><td style=\"white-space:nowrap\">055<a name=\"ssf-2-leukemia-codesystem-055\"> </a></td><td>Myeloid and lymphoid neoplasms with FGFR1 rearrangement</td></tr><tr><td style=\"white-space:nowrap\">090<a name=\"ssf-2-leukemia-codesystem-090\"> </a></td><td>(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">091<a name=\"ssf-2-leukemia-codesystem-091\"> </a></td><td>同時有兩種(含)以上上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">092<a name=\"ssf-2-leukemia-codesystem-092\"> </a></td><td>同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常</td></tr><tr><td style=\"white-space:nowrap\">8XX<a name=\"ssf-2-leukemia-codesystem-8XX\"> </a></td><td>Molecular study after chemotherapy or immunotherapy or target therapy</td></tr><tr><td style=\"white-space:nowrap\">988<a name=\"ssf-2-leukemia-codesystem-988\"> </a></td><td>不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)</td></tr><tr><td style=\"white-space:nowrap\">998<a name=\"ssf-2-leukemia-codesystem-998\"> </a></td><td>有執行分子生物學檢查，但結果無法判斷</td></tr><tr><td style=\"white-space:nowrap\">999<a name=\"ssf-2-leukemia-codesystem-999\"> </a></td><td>(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查</td></tr></table></div>"},"url":"https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem","version":"0.1.0","name":"SSF2leukemiaCS","title":"SSF2 白血病-白血病分子生物學檢查的評估","status":"draft","experimental":false,"date":"2023-09-26T09:09:58+08:00","publisher":"Kuo","contact":[{"name":"Kuo","telecom":[{"system":"url","value":"http://example.org/example-publisher"}]}],"description":"Assessment of molecular studies in leukemia Code System","caseSensitive":true,"content":"complete","count":33,"concept":[{"code":"000","display":"正常"},{"code":"001","display":"AML with RUNX1-RUNX1T1"},{"code":"002","display":"AML with CBFB-MYH11"},{"code":"003","display":"Acute promyelocytic leukemia with PML-RARA"},{"code":"004","display":"AML with KMT2A-MLLT3"},{"code":"005","display":"AML with DEK-NUP214"},{"code":"006","display":"AML with GATA2, MECOM"},{"code":"007","display":"AML(megakaryoblastic) with RBM15-MKL1"},{"code":"008","display":"AML with mutated NPM1"},{"code":"009","display":"AML with biallelic mutation of CEBPA"},{"code":"010","display":"AML with mutated FLT3/ITD"},{"code":"011","display":"AML with mutated FLT3/TKD"},{"code":"012","display":"AML with MLL-PTD (partial tandem duplication)"},{"code":"013","display":"AML with BCR-ABL1"},{"code":"021","display":"B lymphoblastic leukemia/lymphoma with BCR-ABL1"},{"code":"022","display":"B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged"},{"code":"023","display":"B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)"},{"code":"024","display":"B-lymphoblastic leukemia/lymphoma with IGH/IL3"},{"code":"025","display":"B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)"},{"code":"041","display":"Mixed phenotype acute leukemia with BCR-ABL1"},{"code":"042","display":"Mixed-phenotype acute leukemia with KMT2A-rearranged"},{"code":"051","display":"Chronic myelogenous leukemia BCR-ABL1 positive"},{"code":"052","display":"JAK2 V617F mutation"},{"code":"053","display":"Myeloid and lymphoid neoplasms with PDGFRA rearrangement"},{"code":"054","display":"Myeloid and lymphoid neoplasms with PDGFRB rearrangement"},{"code":"055","display":"Myeloid and lymphoid neoplasms with FGFR1 rearrangement"},{"code":"090","display":"(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常"},{"code":"091","display":"同時有兩種(含)以上上述之分子檢驗異常"},{"code":"092","display":"同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常"},{"code":"8XX","display":"Molecular study after chemotherapy or immunotherapy or target therapy"},{"code":"988","display":"不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)"},{"code":"998","display":"有執行分子生物學檢查，但結果無法判斷"},{"code":"999","display":"(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查"}]}